|
UPMC Conflict of Interest, Lilly’s Oral GLP-1, and Whoop Hits $10B
April 9, 2026
|
|
|
|
|
Together with
|
|
|
|
“The words physician and provider are not interchangeable. Provider undermines the physician’s ethical obligations, clinical integrity, and accountability, as well as trust in the patient–physician relationship. The term should not be used to describe physicians, nor should physicians use it to describe themselves, their team members, or their trainees.”
|
|
Sulmasy, et al.
|
|
|
|
UPMC’s structural heart president, Hemal Gada, MD, might have been terminated for whistleblowing, according to a federal lawsuit that alleges retaliatory firing following his reports of conflicts of interest regarding Edwards Lifesciences and alleged racism within UPMC.
- UPMC is the largest non-government employer in Pennsylvania, operating a massive network of over 40 hospitals, 800+ outpatient sites, and 100k employees.
- Since UPMC receives Pennsylvania tax funding, it’s a public body under state Whistleblower Law, protecting employees who report waste or wrongdoing.
- Edwards also has substantial medical device contracts with UPMC that require conflicts to be disclosed to Value Analysis Teams and physicians using Edwards products.
The whistleblower retaliation suit details how Dr. Gada originally criticized Edwards’ SAPIEN 3 valve clinical trial data on LinkedIn in December 2023.
- The LinkedIn posts offered detailed breakdowns of EARLY-TAVR’s shortcomings, an Edwards-funded trial which led to SAPIEN’s FDA approval for asymptomatic AS patients.
- This essentially made Dr. Gada one of the loudest voices advocating against unnecessary TAVR in younger patients.
- Dr. Gada then noticed that Edwards employees and UPMC leadership began viewing his LinkedIn profile.
- Eventually, an external investigation into his social media use found no wrongdoing.
Dr. Gada later met with UPMC’s Value Analysis Team to voice his concerns after discovering the system’s CEO received over $300k in compensation for sitting on Edwards’ board while using the health system’s corporate jet for board meetings, something which was undisclosed to other UPMC leadership.
- Shortly thereafter, UPMC’s counsel closed his complaint without resolution, per the lawsuit.
But Dr. Gada’s troubles with UPMC didn’t end there, and in mid-April 2025, he reported text messages between his colleagues regarding UPMC’s new Interventional Cardiology Fellowship.
- Allegedly, the messages stated that patients dislike brown physicians with accents and expressed concern about replacing white doctors with brown ones.
On August 3rd, 2025, five months after reporting the racist texts, UPMC launched an internal investigation into Gada’s professional conduct, followed by paid suspension on August 6th, and an emergency board termination August 13th.
- This all happened one day before a Medical Executive Committee due process meeting that would have given Dr. Gada a chance to respond to the accusations of misconduct.
The Takeaway
While this lawsuit is fresh and details are still being clarified, it does point to potential conflicts of interest in the largest medical system in one of America’s most developed states. Only time will tell how this case is settled, but right now it reads like punishment for speaking out against improper conduct.
|
|
How Us2.ai Improves CA Screening
Cardiac amyloidosis may not be as rare as previously thought, with early and accurate detection becoming increasingly critical for treatment. Read about how the AI-SCREEN-CA study implemented Us2.ai’s automated CA reporting and AI-based pattern recognition analysis, leading to better disease screening at scale.
|
|
Why Competitors Benchmark Against Monebo’s ECG Algorithm
In the world of cardiac monitoring, it’s a big deal when your competitors use your technology as their benchmark for success. Learn why Monebo Technologies’ ECG analysis algorithm has been the “predicate device” of at least 13 other companies FDA 510(k) clearance regulatory filings and what this means for providers and their patients.
|
|
CMR Access Is Broken — Here’s How to Fix It
Cardiac MRI is one of the most powerful tools for diagnosing heart disease, yet it’s still out of reach for many patients. Download Vista AI’s new infographic to see what’s holding CMR adoption back—and how AI and automation can help make gold-standard imaging more accessible than ever.
|
|
- Whoop’s $10.1B Valuation: Wearable technology leader Whoop secured $575M in financing, backed by Abbott, Mayo Clinic, and global icons like Cristiano Ronaldo, upping its valuation to $10.1B. The screenless, fashion-forward device provides 2.5M subscribers with FDA-cleared ECGs and AI-driven health metrics. Despite a 2025 regulatory dispute with the FDA over its “Blood Pressure Insights” wellness classification, Whoop plans to use the capital to expand globally and deepen its clinical healthcare integration, leveraging a blend of predictive biometrics and high-fashion marketing.
- Eli Lilly’s Foundayo Approval: The FDA approved Eli Lilly’s orforglipron, branded as Foundayo, for once-daily oral chronic weight management in adults with obesity. This approval is the first for a new molecular entity under the FDA’s expedited Commissioner’s National Priority Voucher (CNPV) pilot program. Foundayo also offers a lifestyle advantage over Novo Nordisk’s Wegovy pill, since it can be taken at any time without food or water restrictions. Thanks to the CNPV program, Foundayo is now the fastest-approved molecule since 2002.
- Silly Rabbit! Cholesterol Isn’t for Kids! High cholesterol isn’t something we often think about with kids, but recent NHANES data showed that 16.5% of U.S. youth have abnormal cholesterol. Prevalence is higher in boys (19.2%) and those with obesity (35.8%), with the latter being three times more likely to have abnormal measures than normal-weight peers. Despite these disparities, overall rates of high youth cholesterol have actually decreased since 2013, so we have improved pediatric lipid levels over the last decade.
- CMS Sets Code for AI CAC Analysis: CMS established a new HCPCS code for AI-based analysis of coronary artery calcification and/or aortic valve calcification from chest CT scans. The new code, G0680 status indicator S and APC 1492, creates an official reimbursement pathway for AI-enabled opportunistic CAC assessment in hospital outpatient settings. The move was lauded by companies like HeartLung AI, which make software for performing CAC assessment from routine chest CT scans acquired for other indications.
- Cardiac Imaging Dose Higher in Africa: Previous studies have found that radiation dose from imaging exams in developing countries is often much higher than in developed nations. A study presented at ACC 2026 found that average dose in Africa was shockingly high for coronary CT angiography compared to non-African countries (26 mSv vs. 6.6 mSv), and a higher percentage of African patients were scanned with older CT systems (45% vs. 16%). And if newer CT scanners were used, dose was no lower, unlike other countries.
- Law Enforcement CV Risk Acceleration: A study presented at ACC 2026 revealed that Law Enforcement Professionals face significantly accelerated cardiovascular disease, with heart attacks occurring nearly two decades earlier than in the general population. Analyzing 497 officers, researchers found rapid degradation in BMI, A1c, and cholesterol markers by age 40, plus elevated coronary artery calcium levels starting at 30. Experts urge earlier screening and targeted nutrition for this patient group to help offset the occupational stress and cardiac degradation involved.
- BMJ Retracts Integrity-Compromised Trial: The BMJ retracted PREVENT-TAHA8, which had been investigating the prevention of acute MI-induced HF using stem cells, due to unresolved concerns regarding data integrity and trial reliability. Investigations revealed improbable data patterns, recruitment outside inclusion criteria, and misleading trial registration. The retraction follows the failure of Iranian regulators to independently verify the dataset, alongside revelations of undisclosed competing interests and authorship misconduct.
- Global Hypertension’s Growing Divide: A 20-year meta-analysis of 6.1M adults confirmed that hypertension now affects 1.71B people, with a widening disparity between high-income and low-to-middle-income countries (LMICs). While awareness and control rates rose in high-income regions (reaching 40.2%), LMICs saw prevalence and burden surge, with control rates stagnating at 13.6%. Researchers warn that without urgent intervention, this rising burden could trigger a global wave of preventable heart attacks, strokes, and dementia.
- Preeclampsia’s Aspirin Adherence Gap: A Mass General Brigham study of over 30k pregnancies revealed that only 24% of high-risk patients used preventative low-dose aspirin by 2023, despite guidelines established in 2014. While utilization grew from 4% over a decade, adherence remains low for what is a leading cause of maternal mortality. The analysis suggests there is a critical “systems issue,” particularly for patients with renal or autoimmune diseases.
- Impella’s Clinical Setbacks: Two randomized trials at ACC 2026 failed to show clinical benefits for Johnson & Johnson’s Impella heart pumps in high-risk PCI and heart attack patients, despite the device’s rapid commercial expansion. The CHIP-BCIS3 trial found that routine mechanical support during complex interventions provided no myocardial protection and was associated with a 50% increase in mortality compared to standard care (32.6% vs. 23.4%). Similarly, the STEMI-DTU trial demonstrated that delaying stenting for 30 minutes to “unload” the heart did not reduce infarct size and increased bleeding risks.
- VA Study on HFrEF “Quad” Therapy: A massive 2026 cohort study of over 52k veterans revealed a significant gap between medical guidelines and real-world execution. While “quadruple therapy” (concurrent use of Beta-blockers, RASis, MRAs, and SGLT2is) is the gold standard for HFrEF, fewer than 21.2% of veterans actually achieved this regimen over nearly three years of follow-up. With a median time to therapy of 197 days (~6 months), the study highlighted that life-saving care often moves slowly, hindered by things like medication copays.
|
|
What Every Cardiologist Needs to Watch for in Heart Failure
Patients with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) face a high risk of hospitalization for heart failure and cardiovascular death, even with guideline-directed medical treatment. Hear from Bayer’s Dr. Alanna Morris-Simon as she shares common heart failure signs to look out for.
|
|
The Power of AI in Cardiovascular Imaging
Cardiac labs are under more pressure than ever to deliver more with greater speed and precision. Hear from Tony Gallagher, Director of Noninvasive Cardiology at Baptist Health Lexington about how Siemens Healthineers’ ACUSON Origin is reshaping daily practice and transforming the future of echocardiography.
|
|
Beyond the Calcium Score with Circle CVI
The coronary artery calcium score has been the non-invasive gold standard for a quick look at heart disease risk, but it only tells part of the story. Learn more about how Circle Cardiovascular Imaging is using AI-enabled coronary plaque analysis to redefine heart risk beyond what a CAC score can tell us.
|
|
- From CPACS to CVIS: Cardiovascular imaging has come a long way from CPACS. Explore the evolution of cardiology image and data management in this Merge executive brief, and see what makes CVIS such a significant advancement.
- Earlier Detection, Better Outcomes: When it comes to heart disease, early detection is crucial to a patient’s long-term health. Learn more about how Fujifilm helps clinicians achieve that with the Lisendo 880 cardiovascular ultrasound system’s unique solutions that detect early abnormalities seen in heart failure, while offering insight into cardiac functions and groundbreaking hemodynamic analysis.
- PIA’s Post-Processing Solution: Advanced cardiac imaging often calls for a time-consuming post-processing step, requiring costly software, hardware, and training. See how PIA provides this post-processing at lower cost, improved consistency, and greater efficiency.
- Tempus Receives FDA 510(k) Clearance for Tempus ECG-Low EF: Tempus announces the expansion of its Tempus ECG-AI portfolio with Tempus ECG-Low EF, software intended for use to analyze 12-lead ECG recordings and detect signs associated with having a low left ventricular ejection fraction (LVEF less than or equal to 40%) in patients 40 years of age or older at risk of heart failure. It is not intended as a stand-alone diagnostic and positive results may suggest the need for further clinical evaluation. For Full Indications for Use, visit here.
|
|
|
|
|
